Studies On Kallikrein-kinin System In

Normotensive And Hypertensive Rats With

And Without Diabetes by Kesavarao, Uma
\ 
\ 
I 
\ 
\ 
\ 
\ 
I 
l 
I 
I 
\ 
PERPUSTAKAAN 
UNIVERSITI SAINS MALAYSIA 
Tesis/latihan ilmiah ini <tdalah untuk kajian dan 
penyelidikan sahaja. Bahagian·bahagian, data·· 
data atau idea·idea yang asaldarTl<aryaTnrHiiiik 
§_~h"(}J:Pi!ffi::"a.ta~.!__disefi.U}kiin-tii'ij)33kiJa_n_. __ _ 
Tllis thesis/academic exercise must be used for 
study or research purposes. No J!..Ort~C!..".. of thi§. 
work, on:qinal data or ideas may be t3ken/ 
'l.!!..f!.!Cd w[i!i(jjjf...d_'!faG_kno_vyled_9!!.'!!..ent _______ _ 
i . 
• 
STUDIES ON KALLIKREIN-KININ SYSTEM IN 
NORMOTENSIVE AND HYPERTENSIVE RATS WITH 
AND WITHOUT DIABETES 
' ~ \ I 
by 
UMA KESAVARAO 
Thesis submitted in fulfilment of the 
requirements for the degree 
of Master of Science 
(Pharmacology) 
December 1995 
• 
f 
Oom Gane~aaya Namaha 
< 
-~ .. _. 
-· 
This thesis is dedicated 
to 
my most reverent elders 
Mr. R. Periyaswamy, 
Mr. S. Kesavarao and Mrs. Vasanthi Kesavarao 
and to my most beloved husband 
Dr. S.P. Ram and 
children 
Ranjith and R. Dinesh. 
11 
~-· 
ACKNOWLEDGEMENTS 
• 
It is my duty to acknowledge my heartfelt gratitude to Prof. J.N. 
Sharma, my supervisor, who has been a pillar of support in stimulating 
' and guiding me at all stages of this work. I am indebted to thank him for 
:· imparting his wide experience and knowledge in this field. -
I am thankful to Dr. Abdul Rahman Noor, Head of Department of 
Pharmacology· and co-supervisor of . my research, for his kind co-
operation and providing an oppourtunity to work in his department. 
I am most grateful to Dato' Prof. Mustaffa Embong, Dean of Medical 
School for his kind support and providing an opportunity to work for 
higher degree. This work was supported by a research and development 
grant from the Ministry of Science and Technology o.f Malaysia, under 
the Sixth Malaysian Plan (IRP A)_ to-Professor .J .N .Sharma. 
My sincere thanks to Puan Che Nin, Encik Lokman Ali, Encik 
J arrlmalludin Ramli, Encik Abdul Razak, Encik Mohd. Aminorddin, En. 
Mohd Lukmi, Puan Shaheela and En.Shahrul, Department of 
Pharmacology for their support during the course of :my study. 
I am also indebted to acknowlege Dr.Afifi, Vetenerian and En. 
Maarof, School of Medical Sciences, Kubang Kerian, for providing and 
taking care of the animals,and to the Staff of the Department of 
Chemical pahology and histopathology for rendering their help and 
allowing me to utilize their laboratory services. 
I sincerely thank Cik Noor Syamsinaz, Prof. Madya Dr.and Mrs 
Sirisinghe and Puan Ajindar Kaur who have given their support and,,. 
encouragement in completing this task. 
I also thank En.Saaban Mohd.Shukor, En.Izahani Musa and En.Arifin 
Harun from the CAl Laboratory and other staff of the School of Medical 
. 
Sciences ,USM ,Kubang Kerian,Kelantan for their help in completing this 
thesis; - ·· -· 
iii 
CONTENTS 
LIST OF FIGURES 
LIST OF TABLES 
ABSTRAK 
ABSTRACT 
INTRODUCTION 
jy 
1. The kallikrein kinin system 
1.1 · A brief history 
1.2.Chemistry and characterization 
1.2.1 Bradykinin and its analogues 
1.2.2 T -kinin 
1.2.3 Other mammalian kinin 
1.2.4 Non-mammalian kinins 
1.3.Kinin-forming enzymes 
1.3 .1 Plasma kallikrein 
1.3.2 Plasma kallikrein inhibitor 
1.3.3 Tissue kallikrein 
I 1.3.4 Tissue kallikrein inhibitors 
1.3.5 T-kininogenases 
1.3.6 T-kinin inhibitors 
1.4. Plasma Kininoge~s .. ·. l;,~:,.:~ · 
. 1.4.1. Types of kininog'ens ' 
1.4.1a High molecular-weight kininogen 
1.4.1b Low molecular-weight kininogen 
l.4.1c T-kininogen 
1.5.Fate of kinins 
1.5.1 Kininases 
1. 6. Role of kinins 
1.6.1 Physiological conditions 
1.6.2 Pathological conditions 
iv 
X 
• 
xvi 
xvii 
xix 
1 
2 
4 
6 
6 
6 
7 
7 
10 
11 
12 
12 
14 
15 
16 
16 
16 
16 
16 
18 
19 
19 
·~--
20 
20 
22 
v 
1. 7. The Antihypertensive agent-
Angiotensin converting enzyme inhibitors 
' 2. AIM OF THE PRESENT STUDY 
3. MATERIALS 
4. METHODS 
4 .1. Experimental methods 
4.1.1 Animal model 
4.1.2 
4.1.3 
4.1.4 
Recording blood pressure and removal of heart 
Induction of Diabetes 
Administration of captopril 
4.2.ESTIMATION OF KALLIKREIN-KININ 
COMPONENTS 
I 
4.2.1.Determination of tissue kallikrein activity 
4.2.1a Preparation of standard curve 
4.2.1b Preparation of cardiac tissue homogenate 
4.2.1c Determination of Active Tissue Kallikrein 
4.2.1d Determination of Total Tissue Kallikrein 
4.2.1e Estimation of Inactive Tissue Kallikrein 
4.2.2.Estimation of cardiac tissue kininogen 
activity 
4.2.3. Determination of plasma prekallikrein activity 
and kallikrein-like activity 
.. './'"::>:· ' 
Preparatio,n, Qf ~tijqp~~~ .<:;urve of plasma kallikrein 
activity ~~i/·)\i·~f~~~~·~j~;1 '£1,(/;'. 
Determil1~tio~f~{rrX~~~~ ;l,liekallikrein Activity 
. - ~- . -· ··-- ,.-:,. ",... ··> .. --.:~ ... : .. r~·.~\1~!,1r;\_:~~:·: .... :_~-,';,;)·:.~lA:--
Determiriation qt;Pt~~rl1a Kallikrein-Like Activity 
.. ~~~(,~·~F-~- ~:>· . 
4.2.3a 
4.2.3b 
4.2.3c 
v 
• 23 
25 
27 
29 
29 
29 
29 
30 
30 
31 
31 
32 
33 
34 
34 
34 
35 
36 
37 
38 
38 
vi 
4.2.4 •. Determination. bf:.p~a~.ma kallikrein inhibition 
activity 
4.2.4a 
4.2.4b 
I ':;i·~,' ;•:\_,,~;;'~· .. :.','·.~,~\' ,i 
• 39 
39 
ltcrem Inhibition Activity 41 
kininogens 41 
4.2.5a 42 
4.2.5b 43 
4.2.5c Estimation of high molecular weight plasma Kininogen 4 4 
-- 4.2.5d Estimation of low molecular weight plasma Kininogen 4 4 
4.2.6.Determination of uri!l~ ·kallikrein 4 4 
4.2.6a Preparation of standard Curve 4 5 
4.2.61? Determination of Active Urinary Kallikrein 4 6 
4.2.6c Determination of Total Urinry Kallikrein 
\4.2.6d Estimation of Urinary prokallikrein 
4.2.7.MORPHOLOGICAL EVALUATION OF THE HEART 
4.2.7a Preparation of slide~ 
4.2.7b Staining with haematoxylin and eosin 
4.2.7c Measurement of left ventricular wall thickness 
4.2.8. Statistical analysis 
5.RESULTS 
S.l.STANDARD CURVES 
5.1.1 Urinary kallikrein activity 
5 .1.2 Tissue kallikrein 
5 .1. 3 Plasma kallikrein 
5. 1'.4 ·-· J?l~sm.ak<:tllikrein inhibitory activity 
5.1.5 Bradykinin 
vi 
47 
47 
47 
47 
47 
48 
50 
51 
51 ..• 
51 
51 
55 
55 
55 
v\i 
5.2.ALTERATIONS IN KALLIKREIN-KININ SYSTEM 
IN NORMOTENSIVE WISTAR KYOTO AND 
SPONTANEOUSLY HYPERTENSVE RATS WITH 
AND WITHOUT DIABETES 
5.2.1. Subjects characteristics 
5.2.1a Urine glucose 
5.2.lb Urine total protein 
5.2.1c Blood glucose 
5.2.2.Blood pressure 
5 .2.2 a Systolic blood pressure 
5.2.2 b Diastolic blood pressure 
5.2.2 c Mean arterial pressure 
5.2.3. Urinary kallikrein activity 
5.2.3a Active 
5.2.3b Total 
5.2.3c Prokallikrein 
5.2.4.Plasma kallikrein activity 
5.2.4a Prekallikrein activity 
5.2.4b Kallikrein-like activ~ty 
5.2.5.Plasma kallikrein inhibitory activity 
5.2.6.Cardiac tissue kallikrein 
' 
5.2.6a Active 
5.2.6b Total 
5.2.6c Inactive 
5.2.7.Cardiac tissue kininogen 
5.2.~.Plasma kininogens 
5.2.8a · Total plasma kininogen 
5.2.8b High molecular weight kininogen 
vii 
• 
59 
59 
59 
60 
60 
60 
60 
60 
65 
65 
65 
69 
69 
73 
73 
73 
73 
73 
73 
76" 
76 
76 
76 
81 
81 
5.2~8c Low molecular weight kininogen 81 
5.2.8d Plasma Bradykinin • 81 
5.2.9.Measurement of left ventricular wall thickness 83 
including interventricular septum 
5.3.EFFECTS OF CAPTOPRIL ON NORMOTENSIVE 8 3 
WISTAR KYOTO AND SPONTANEOUSLY 
HYPERTENSIVE RATS WITH AND WITHOUT 
DIABETES 
5.3.1.Subjects characteristics 
5.3.1a Blood glucose 
5.3.lb Urine protein and glucose 
5.3.2.Blood pressure 
5.3.2a Systolic blood pressure 
'6.3.2b Diastolic blood pressure 
5.3 .2c Mean arterial pressure 
5.3.3. Urinary kallikrein activity 
5.3.3a Active urinary kallikrein 
5.3.3b Total urinary kallikrein 
5.3.4.Plasma kallikrein activity 
5.3.5.Plasma kallikrein inhibitory activity 
5.3.6.Plasma kininogens and bradykinin 
5.3.6a Total kininogen 
5.3.6b High molecular weight kininogen 
5.3.6c Low molecular weight kininogen 
viii 
83 
84 
84 
88 
88 
92 
92 
97 
97 
102 
102 
107 
107"" 
107 
114 
ix 
'i~ i''' 5.3.7.Measurement of left ventricular wall thickness 114 
including interventricular septum 
• 
6.DISCUSSION 115 
7 .CONCLUSION 121 
-·-
S.REFERENCES 1 
9.APPENDICES 
10.PUBLISHED PAPERS AND COMMUNICATIONS 
ix 
List. of figures 
• Figurel.l. Formation and destruction of kinins .......................... 3 
Figure 4.1. Measurement of left ventricular wall thickness including 
interventricular septum by projecting the image of its sJide on to a 
calibrated screen ........................................................... .-.......... 49 
Figure 5.1. Standard curve for urinary kallikrein activity using 
standard pancreas kallikrein . Absorbance (y .axis) was plotted against 
different concentration of standard pancreas kallikrein ·ex axis) ..... 52 
Figure 5.2. Optimation of time for rate assay of tissue kallikrein 
activity. Time in minutes (x axis) was plotted against increase in 
absorbance (y axis) ................................................................... 53 
Figure 5.3. Standard curve for tissue kallikrein using standard pancreas 
kallikrein .. Different concentrations of standard pancreas kallikrein (x 
axis) were plotted against increase in absorbance at 405nm(y 
akis) ....................................................................................... 54 
Figure 5.4. Standard curve fer plasma prekallikrein and kallikrein-like 
activity . Different concentrations of standard plasma pool (x axis) were 
plotted against absorbance at 405nm (y axis) ............................. 56 
Figure 5.5. Standard curve for plasma kallikrein inhibition activity. 
Different concentrations of standard plasma pool (x axis) were plotted 
against absorbance at 405nm (y axis) ......................................... 57 
Figure 5.6. Standard curve for measurement of bradykinin, total, high 
molecular weight kininogen and low molecular weight kininogen usil}~ 
Markit M bradykinin kit. ........................................................... 58 
Figure 5.7. Changes in systolic blood pressure in diabetic Wistar kyoto 
and diabetic spontaneously hypertensive rats compared to control Wistar 
kyoto and control spontaneously hypertensive rats ................. : ....... 62 
• 
xi 
l Figur~ 5.8. Changes in diastolic blood pressure in diabetic Wistar kyoto 
':: ~ 
~:.·:' 
and diabetic spontaneously hypertensive rats compared with control 
• Wistar kyoto and control spontaneously hypertensive rats .............. 63 
Figure 5.9. Changes in mean arterial pressure in diabetic Wistar kyoto 
and diabetic spontaneously hypertensive rats compared to coqtrol Wistar 
kyoto and control spontaneously hypertensive rats .............. : ......... 64 
Figure 5.10. Level of active urinary kallikrein activity in diabetic 
Wistar kyoto and diabetic spontaneously hypertensive rats compared to 
control Wistar kyoto and control spontaneously hypertensive rats .... 66 
Figure 5.11. Level of total urinary kallikrein activity in control Wistar 
kyoto, diabetic Wistar kyoto, control spontaneously hypertensive rats 
and diabetic spontaneously hypertensive rats ................................ 67 
Figure 5.12.Urinary level of total, active and prol\allikrein activity in 
control Wistar kyoto, diabetic Wistar kyoto, control and diabetic 
spontaneously hypertensive rats .................................................. 68 
\ 
Figure 15.13. Changes in plasma prekallikrein activity associated with 
control and diabetic Wistar kyoto and control and diabetic spontaneously 
hypertensive rats ...................................................................... 70 
Figure5.14.Changes in plasma kallikrein inhibition acitvity in diabetic 
Wistar kyoto and diabetic spontaneously hypertensive rats compared to 
their respective nondiabetic controls .......................................... 71 
Figure 5.15. Changes in active cardiac tissue kallikrein activity 
associated with diabetic Wistar kyoto and diabetic spontaneously 
hypertensive rats compared to their respective nondiabeti~,. 
controls .................................................................................. 72 
Figure 5.16. Changes in total_<~ardiac tissue kallikrein activity associated 
with diabetic Wistar kyoto and diabetic spontaneously hypertensive rats 
compared to control Wistar kyoto and control spontaneously 
hypertensive ··rats.-:; .. · .............................................................. 74 
xi 
':>.ii 
Figure 5.17. Level of cardiac tissue kininogen in control and diabetic 
Wistar kyoto and control and diabetic spontaneously hypertensive 
rats ......................................................................................... 7"5 
-·~ 
Figure 5.18.Changes in total plasma kininogen associated with diabetic 
Wistar kyoto and diabetic spontaneously hypertensive rats c,ompared to 
their respective nondiabetic controls................................ - ... 77 
Figure 5.19. Changes in high molecular weight plasma kininogen 
associated with diabetic Wistar kyoto and diabetic spontaneously 
hypertensive rats compared to their respective nondiabetic 
controls .................................................................................. 78 
Figure 5.20 .. Changes in low molecular weight plasma kininogen 
associated with diabetic Wistar kyoto and diabetic spontaneously 
hypertensive rats compared to their respective nondiabetic 
controls ................................................................................. 79 
Figure 5.21. Level of plasma bradykinin in control and diabetic Wistar 
kybto and control and diabetic spontaneously hypertensive 
rats ....................................................................................... 80 
Figure 5.22. Changes in left ventricular wall thickness associated with 
diabetic Wistar kyoto and diabetic spontaneously hypertensive rats 
compared to their respective nondiabetic controls ..................... 82 
Figure 5.23. Effect of different doses of captopril on systolic blood 
pressure of nondiabetic Wistar kyoto and diabetic Wistar kyoto rats 
compared with their respective non treated controls ................. 85 
Figure 5.24.Effect of different doses of captopril on systolic blood 
.~.,. 
pressure of nondiabetic spontaneously hypertensive rats and diabetic 
spontaneously hypertensive rats compared with their respective 
non treated 
controls ............................................................................... 86 
Figure 5.25. Changes in diastolic blood pressure of nondiabetic Wistar 
kyoto and diabetic Wistar kyoto rats with different doses of captopril 
compared with their respective nontreated controls ................. 87 
xii 
·Figure 5.27. Changes in mean arterial pressure of nondiabetic Wistar 
kyoto and diabetic Wistar kyoto rats with different doses of captopril 
compared with their respective non treated controls ....................... 90 . 
Figure 5.28. Effect of different doses of captopril on mean arterial 
pressure of nondiabetic spontaneously hypertensive rats and diabetic 
spontaneously hypertensive rats compared with their respective 
nontreated controls .................................................................. 91 
Figure 5.29. Urinary levels of active kallikrein activ~ty in nondiabetic 
Wistar kyoto and diabetic Wistar kyoto rats treated with different doses 
ofcaptopril compared with their respective nontreated controls ..... 93 
Figt\re 5.30. Urinary levels or active kallikrein activity in nondiabetic 
spontaneously hypertensive rats and diabetic spontaneously hypertensive 
rats treat~d with different doses of captopril compared with their 
respective nontreated controls ................................................... 94 
Figure 5.31. Effect of different doses of captopril on total urinary 
kallikrein activity in nondiabetic Wistar kyoto and diabetic Wistar kyoto 
rats compared with their respective nontreated controls ................ 95 
Figure 5.32. Effect of different doses of captopril on total urinary 
kallikrein activity of nondiabetic spontaneously hypertensive rats and 
diabetic spontaneously hypertensive rats compared with their respective. T 
non treated controls ..................................................... ; .............. 96 
Figure 5.33. Changes in plasma prekallikre1n activity associated with 
nondiabetic Wistar kyoto and diabetic Wistar kyoto rats treated with 
different doses of captopril compared with their respective nontreated 
controls.: .. ;-~· .. ;.;:·.;:: .. ;·;.;· ............................................... .-............. 9 8 
xiii 
xiv 
· Figure 5.34. Changes in plasma prekallikrein activity associated with 
I 
·nondiabetic spontaneously hypertensive rats and diabetic spontaneously 
\: 
hypertensive rats treated with different doses of captopril compared 
with their respective non treated controls .............................. 99 
Figure 5.35. Changes in plasma kallikrein inhibition activity ~ssociated 
with nondiabetic Wistar kyoto and diabetic Wistar kyoto -rats treated 
with different doses of captopril compared with their respective 
nontreated controls ............................................................. lOO 
Figure 5~36. Level of plasma kallikrein inhibition activity in the 
nondiabetic spontaneously hypertensive rats and diabetic spontaneously 
hypertensive rats treated with different doses of captopril compared 
with their respective nontreated controls .................................. lOl 
Figure 5.37. Plasma .level of total kininogen in no:qdiabetic Wistar 
kyoto and diabetic Wistar kyoto rats treated with different doses of 
captopril compared with their respective nontreated controls ... l03 
Figure 5.38. Plasma level of total kininogen in• nondiabetic 
spontaneously hypertensive rats and diabetic spontaneously hypertensive 
rats treated with different dm;es of captopril compared with their 
respective nontreated controis:).J,;~:.: .. : .. ;;............................. 104 
.,.,.1 ..... ;.; ' . ' 
Figure 5.39. Changes in plasma levels of high molecular weight 
kininogen associated with nondiabetic Wistar kyoto and diabetic Wistar 
kyoto rats treated with different doses of captopril compared with their 
respective nontreated controls ............................................... 105 
Figure 5.40.Changes in plasma level of high molecular. weight 
kininogen associated with nondiabetic spontaneously hypertensive rats 
and diabetic spontaneously hypertepsive rats treated with. different doses .. ~ 
of captopril compared with their respective nontreated 
controls ................................................................ : ............. 1 06 
Figure. 5.41. Plasma level of low molecular weight kininogen in 
nondiabetic-- Wistar kyoto and diabetic Wistar kyoto rats treated with 
different doses of captopril compared with their respective nontreated 
controls ............................................................................. lOS 
xiv 
XV 
Figure 5.42. Plas~a level of low molecular weight kininogen in 
t 'nondiabetic spontaneously hyperten~ive rats and diabetic spontaneously 
i 
i~ hypertensive rats treated with dffferent doses of captopril compared 
r: >with their respective nontreated controls .............................. 109 
. 
Figure 5.43. Level of plasma bradykinin in nondiabetic Wistar kyoto 
and diabetic Wistar kyoto rats treated with different doses of captopril 
compared with their respective non treated controls ................ 110 
Figure 5.44. Level of plasma bradykinin ~n the nondiabetic 
spontaneously hypertensive rats and diabetic spontaneously hypertensive 
rats treated with different doses of captopril compared with their 
respective non treated controls ............................................. 111 
Figure 5.45. Changes in left ventricular wa~l thickne~s in nondiabetic 
Wistar kyoto and diabetic Wistar kyoto rats treated with different doses 
of captopril compared with their respective nontreated controls ... 112 
Figrlre 5.46.Changes in left ventricular wall thickness in nondiabetic 
spontaneously hypertensive and diabetic spontaneously hypertensive rats 
treated with different doses of captopril compared with their respective 
non treated control. ............................................................ 113 
.. 
XV 
LIST OF TABLES 
r;·.: 'i 
Table 4.1. Steps in:.'dililtiqn of standard pancreas kallikr.ein m 
preparation of activity .... 31. 
Table 4.2. Steps in · 
tissue kallikrein acti 
Table 4.3. Experi 
measurement of tissue· .... '· ............ ,,'-'-
................... , .... t of active and total 
. 
' ........................ .-.. 32 
. on of cardiac tissue for 
kininogen ............ 33 
Table 4.4. Preparation of different percentages of the standard plasma 
pool for establishing the standard curve for plasma prekallikrein and 
kallikrein-like activity ....................................................... 37 
Table 4.5. Procedure for _~p.easurement of pla~ma prekallikrein 
activity ............................................................................. 38 
Table 4.6. Preparation of different percentages of standard plasma pool 
fof. establishing standard curve for plasma kallikrein inhibitory 
activity............................................................................ 40 
Table 4. 7. Procedure for measurement of plasma kallikrein inhibition 
activity .................................... ~ ........................................ 41 
Table 4.8. Steps in dilution of standard pancreas kallikrein in 
preparation of standard curve for urinary kallikrein 
activity ............................................................................. 45 
Table 4.9. Procedure for measurment of total and active urinary 
kallikrein activity ............................................................. .46 
xvi 
ABSTRAK 
• 
KAJIAN SISTEM KALLIKREIN-KININ DALAM 
TIKUS-TIKUS NORMOTENSI DAN HIPERTENSI DENGAN 
DAN TANPA DIABETES 
Penyelidikan ini bertujuan untuk mengkaji fungsi sistem kallikrein-
kinin dalam tikus-tikus normotensi dan hipertensi dengan dan tanpa 
diabetes. Lanjutan dengan itu pengaruh sistem kallikrein-kinin ke atas 
kesan perencat enzim.penukar angiotensin (ACE inhibitor), captopril ke 
atas diabetes dan hipertensi juga ditentukan. 
Tikus-tikus Wistar kyoto dan hipertensi spontan .telah di-induskan 
diabetes untuk selama lima minggu dan dibandingkan dengan haiwan 
kawalan tanpa diabetik masing-masing. Tekanan darah kedua-dua 
kumpulan tikus Wistar kyoto dan hipertensi spontan telah meningkat 
derlgan signifikennya (p <0.001). Kallikrein urin aktif telah menurun 
dengan signifikan (p <0.001) pada tikus-tikus diabetes Wistar kyoto dan 
hipertensi spontan (SHR). Buat pertama kalinya penyelidikan kami 
mendapati ada penurunan kedua-due jenis kallikrein total dan aktif pada 
tisu kardiak dalam tikus-tikus Wistar kyoto diabetes, hipertensi spontan 
diabetes bila dibandingkan dengan tikus Wistar kyoto kawalan. 
Walaubagaimana pun prekallikrein plasma dan kininogen berat molekul 
-tinggi (LMWK) telah meningkat secara signifikan dalam kumpulan 
diabetik bila dibandingkan masivg-masing kumpulan kawalan tanpa 
diabetik. Penganggaran morfologi jantung mendapati adanya peningkatan 
pada ketebalan dinding ventrikel kiri pada tikus-tikus Wistar kyoto 
diabetes,_ hipertensi spontan dan hipertensi spontan yang berdiabetes .... 
berbanding dengan tikus Wistar kyoto kawalan. 
Pengaruh sistem kallikrein-kinin ke atas perencat enzim penukar 
angiotensin, captopril yang diberi dalam dua dos berlainan, 40mg!kg dan 
80mglkg berat badan untuk selama lima minggu bagi keaua -dua 
kumpulan -tikus diabetik , Wistar kyoto dan hipertensi spontan telah 
dibandingkan dengan kumpulan tikus tanpa diabetik Wistar kyoto dan . 
hipertensi spontan yang juga diberi captopril mendapati; Penurunan 
xvii 
;.;. vl!1 
tekan~n darah dan gula darah yang signifikan (**p <0.001) telah dapati 
pad.a tikus-tikus diabetik, Wistar kyoto dan hipertensi spontan yang telah 
• diberi captopril. Kedua-dua aktif dan total kallikrein pada urin telah 
meningkat kumpulan-kumpulan diabetik yang dirawat dengan captopril. 
Prekallikrein plasma dan kininogen berberat molekul tinggi telah 
didepresikan dalam kedua-dua tikus diabetik, Wistar kyoto dap hipertensi 
spontan berbanding dengan kawalan masing-masing. · Pengukuran 
ketebalan dinding ventrikel kiri menunjukan tiada perubahan hipertrofi. 
Suka dinyatakan yang captopril pada dos 40mg/kg dapat menghalang 
hipertrofi ventrikel kiri tetapi gagal untuk menghasilkan normalisasi 
tekanan darah pada tikus-tikus hipertensi spontan yang diabetik. 
Kajian ini mengesahkan terdapatnya pengawalan yang tidak normal 
sistem kallikrein kinin dalam diabetes dan hypetensi, juga terdapat 
pengaruh yang jelas dari sistem ini terhadap antihipertensi, hypoglisemia 
dan kesan kardioprotektif , enzim perencat pengubah. angiotension iaitu 
captopril. Mekanisma yang mungkin berlaku terhadap komponen kinin 
dalam keadaan patologi ini dan perawatannya telah dibincangkan . 
. -~ 
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ABSTRACT 
This research investigated the role of kallikrein-kinin system in 
normotensive and hypertensive rats with and without diabetes. 
<·.Furthermore, the influence of kallikrein-kinin system on the effects of 
angiotensin converting enzyme inhibitor, captopril on diapetes and 
hypertension were evaluated. 
Diabetes was induced in Wistar kyoto and spontaneously hypertensive 
rats by a single intraperitoneal injection of streptozocin 50mg/kg, 
followed up for five weeks and compared with respective nondiabetic 
controls. Blood pressure was significantly elevated (**p < 0.001) in the 
diabetic groups of both Wistar lcy_oto and spontaneously hypertensive rats 
compared wit their respective nondiabetic controls .. Active urinary 
kallikrein was. significantly depressed in the diabetic Wistar kyoto and 
diabetic spontaneously hypertensive rats (**p < 0.001). For the first time, 
to our knowledge, this research has revealed a lo\Vering of cardiac 
tissue kallikrein, both total and active, in diabetic Wistar kyoto, 
spontaneously hypertensive rats and diabetic spontaneously hypertensive 
rats when compared to control Wistar kyoto rats. However, the plasma 
prekallikrein and high molecular weight kininogen were raised 
significantly in the diabetic groups when compared to respective 
nondiabetic controls of both Wistar kyoto and spontaneously hypertensive 
rats. Morphological estimation of heart revealed an increase in left 
ventricular wall thickness including the interventHcular septum thus 
indicating hypertrophic changes in the diabetic Wistar kyoto, 
spontaneously hypertensive rats and diabetic spontaneously hypertensive 
rats when compared to control Wistar kyoto rats. 
Influence of kallikrein-kinin system on angiotensin converting 
enzyme inhibitor, captopril, administered in two different doses, 
40mg/kg and 80mg/kg body weight for five weeks in diabetic rats both 
Wistar kyoto and spontaneously hypertensive groups was compared with 
nondiabetic control Wistar kyoto and control spontaneously hypertensive',. 
rats treated with captopril. A significant decrease (**p < 0.001) in blood 
pressure and blood sugar was observed in the· diabetic Wistar kyoto and 
diabetic spontaneously hypertensive rats treated with captopril. The 
urinary. kallikrein, both active and total were increased in the diabetic 
Wistar kyoto and· spontaneously hypertensive rats treated with captopril. 
Total and active cardiac tissue kallikrein were significantly 
decreased(p<0.001)in ··the diabetic groups .when compared to their 
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respec~ive nondiabetic controls. Plasma prekallikrein and high molecular 
weight kininogen were depressed in both diabetic Wistar kyoto and 
diabetic spontaneously hypertensive rats when compared to" their 
respective control.Measurement of left ventricular wall thickness showed 
no hypertrophic changes in diabetic Wistar kyoto, control spontaneously 
hypertensive rats and diabetic spontaneously hypertensive ~ats treated 
with captopril. It is of interest to note thae captopril at a dose of 40mglkg 
which prevented left ventricular hypertrophy failed to produce 
normalization of blood pressure in the diabetic spontaneously 
hypertensive rats. 
Our study confirms the abnormal regulation of kallikrein-kinin system 
in diabetes and hypertension and a definite influence of this system on the 
antihypertensive, hypoglycemic and cardioprotective effects of 
angiotensin converting enzyme inhibitor, captopril. The possible 
mechanisms of action of kinin components in these pathological 
conditions and their treatment have been discussed. 
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INTRO:pUCTION 
The diversity and significance of recent researches on the kalliKrein 
kinin system has provided the impetus for, understanding of the 
pathophysiological processes of human diseases. The kallikrein-kinin 
sy~tem can no longer be regarded as an isolated system. T~e recent 
introduction of specific bradykinin receptor subtype antagonists has 
greatly advanced our understanding of the kallikrein-kinin system in 
various physiological and pathological conditions. Early studies 
focussed on the role of kinins in shock, inflammation· and the function 
of exocrine glands. Interest has broadened recently as the numerous 
studies over the last few years have demonstrated the participation of 
kallikrein-kinin system in essential hypertension, aldosteronism, diabetes 
mellitus, asthma and rheumatoid arthritis. Our study is focussed on the 
role of kinins and the effects of angiotensin converting enzyme inhibitors 
on hypertension and diabetes mellitus in experimental anip1als. 
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l.The KALLIKREIN KININ SYSTEM 
Kinins are paracrine peptides derived from circulating precursefrs by 
.. the action of serine proteases called kininogenases or kallikreins 
(Sharma, 1988a,b). They participate in a wide range of functions 
including the regulation of local organ blood flow, systemic blood 
pressure, transepithelial water and electrolyte transport, cellular growth, 
capillary permeability and inflamm-atory responses. Once released into 
the circulation, the kallikreins are rapidly inactivated by a group of 
plasma protease inhibitors, while kinins in circula~ion are destroyed by a 
group of enzymes known as kininases (fig.l.l). 
The two most potent kallikreins are plasma and tissue 
kallikreins. Tissue kallikrein is present in organs like the kidney, brain 
and heart. When released into the circulation, it releases kinin before 
being inactivated by plasma inhibitors (Scicli et al.,l983). Plasma 
kallikrein is found in plasma in zymogen form and ~iffers from tissue 
kallikrein in its biochemical and functional properties. In addition to 
kinin releasing function, it is associated with coagulation, fibrinolysis and 
inactivation of the complement system (Sundsmo and Fair.,1983). 
the two main forms of kininogens or kallikrein substrates are low 
molecular-weight kininogen and high molecular-weight kininogen, both 
of which are found in plasma. A rat kininogen (T -kininogen) has been 
identified as a major acute phase reactant of inflammation (Muller-
Ester! et a1.,1986). 
Kinins are produced from the kininogen substrates by the plasma 
and tissue kallikreins and other kininogenases. The important kinins 
described in mammals are:- bradykinin, lys-bradyldnin, met-lys-
bradykinin, hyp-lys-bradykinin, and ile-ser-bradykinin (T-kinin). 
The kinins are rapidly destroyed by enzymes known as kininases 
found in blood, endothelial cells and other tissues. The main kininases are 
kininase I, an arginine carboxypeptidase and kininase II, also known as 
angiotensin I converting enzyme. 
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AMINO PEPTIDASE 
(Plasma&. Urine) + KALLIDIN 
Figure 1. 1 Formation and destruction of kinins. 
(HF: Hageman factor) 
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1.1. A brief history 
The history of kallikrein kinin system dates back to the early 20th 
century when Abelous and Bardier (1908, 1909 a,b,c,d.) detected the 
presence of a hypotensive substance in normal human urine which they 
called urohypotensin. In 1926, Frey observed a considerable. reduction 
in blood pressure when the urine of human or any other mammals was 
injected into dogs. Together with Kraut (Frey and Kraut, 1928) and 
Schultz (Frey et al., 1930) he isolated the causative substance from 
human urine and other organs. This hormone type substance was called 
'kallikrein' after the greek synonym for pancreas as it occurred in high 
concentrations in this organ. A short time after the discovery of 
kallikrein, Frey and Kraut (Kraut et al., 1928) found an inactivator of 
this substance in the blood, which blocked the efficacy of kallikrein by 
being bound to it, the formed complex releasing the substance again on 
acidification. This led to the discovery of a potent ~allikrein inhibitor 
in bovine organs (Bauer et al., 1929; Kraut et al., 1930) which was 
later known as Aprotinin or Trasylol. 
A further mile-stone in the history of kallikrein-kinin system was 
the\publication by Werle et al., (1937) who foundthat kallikrein did not 
act directly but released an effector substance from an inactive 
precursor in plasma to produce contraction of isolated smooth muscle 
preparation of guinea pig, ilieum.This substance, thought to be a 
polypeptide, was initially: called' . De'rmkontrahieirende substanz (gut 
contracting substance, substanz D.K). Werle and Berek (1948) later 
renamed it kallidin, and its inactive precursor kallidinogen. Much later, 
it was shown by Werle et al., (1961) and by. Pierce and Webster 
(1961) that kallidin, a decapeptide, was the lysyl derivative of 
bradykinin. Bradykinin was first described by Rocha e Silva et al., 
(1949), in Brazil. They found that incubating dog plasma with venom of 
certain snakes and trypsin produced a polypeptide with hypotensive and 
-smooth muscle contracting properties. Kallidin .and bradykinin were' 
found to be derived from the same substrate (Werle et al.,1953). The 
purification and synthesis of these substances, a decade later, confirmed 
that the trypsin or snake venom - bradykininogen - bradykinin system 
and kallikrein- kaliidinogen- kallidin system were closely relaled (Elliot 
et al., -1960a; Boissonass et al.,1960a). The adoption of the generic 
name "kinins" for the whole group (Schachter and Thain, 1954) led to 
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the use of the term'"kininogenases" for such enzymes as kallikrein, 
trypsin, snake venom enzyme and bacterial proteases which released 
·· kinin from an inactive protein substrate known as "kininogen". • 
In 1965, a third kinin, met-lys-br~dykinin, was found by Elliot and 
Lewis in acidified ox plasma. It bore one additional methionyl group at 
the amino end of the·. kallidin molecule (Erdos 1970). Many different 
free kinin& of non-mammalian origin were found first by- Erspamer in 
amphibians (Anastasi et al., 1966) and then by Schachter in some 
insect venoms (Jaques and Schachter, 1954). Much later another kind of 
kinin was found by Greenbaum, liberated from the lysosomes of 
polymorphonuclear leucocytes (Chang et al., 1972).This polypeptide 
did not have the classical kinin sequence. It was called 'leukokinin' 
and its precursor leukokininogen. In 1983, Okamoto and Greenbaum 
found that trypsin in high quantities released a kinin, 'T-kinin' (T for 
trypsin-releasing) and that it constituted 70% of rat plasma kinins. This 
kinin was found to increase eight to ten fold ~n cases of acute 
inflammation (Okamoto and Greenbaum,1986). 
The kinins and thus the kallikreins, in minute amounts, controlled 
essential physiological functions in the body. Excessive kinin formation 
wa~ prevented by kininases and kallikrein inhibitors. Modern methods of 
biochemistry and molecular biology have provided us with a detailed 
knowledge of the kallikrein-kinin system and its components. The vital 
importance of this system for fundamental mechanisms in biochemistry, 
pharmacology, cell-biology which are of great interest and practical 
benefit to medicine has resulted in great involvement in -research in this 
field. 
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->1.2 Chemistry and .Ch~i~tterization of kinins 
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'·· 1.2.1 Bradykinin and . 
Plasma kinins are polypeptides which 
, resemble bradykinin logical properties 
(Webster,1966a).The bradykinin, 'kallidin, 
methionyl-iysyl leukokinin, T-kinin, and 
other mammalian and . . . . Bradykinin is a 
nonapeptide with an amino · -:of N,Arg-Pro-Pro-Gly-Phe-
Ser-Pro-Phe-Arg,OH (Boissonass et al., 1963) and molecular weight of 
1131 (Elliot et al., 1960b). Kallidin is a decapeptide having an 
additional N-terminal lysine residue (Pierce and Webster, 1961; Pless 
et al, 1962). Acidification of ox plasma to pH 2.5 for several days and 
suJ?sequent neutralization yeilds a hendecapeptide methionyl-lysyl-
. bradykinin (Elliot et al.,1963). Two high molecular weig.ht peptides have 
been isolated from incubates of- liuman kininogen with an enzyme 
fraction of macrophages and polymorphonuclear leucocytes at pH 4.0 
(Chang et al., 1972). Leukokinin M (macrophage enzyme mediated) has 
twenty five aminoacids and a molecular weight of 2826. Leukokinin 
PMN (PMN-cell enzyme mediated) has twenty one aminoacids and a· 
molecular weight of 2416. 
1.2.2 T-kinin (Ile-Ser-Bradykinin) 
Trypsin in large quantities liberates T -kinin (T for trypsin-
releasing) along with a small quantity of bradykinin from rat plasma 
(Okamoto and Greenbaum,1983a).The structure of the undecapeptide is 
Ile-Ser-Arg-Pro-Pro-Gly-Phe-Pro-Phe-Arg (isoleucyl-seryl-bradykinin) 
(Okamoto and Greenbaum, 1983b).The two protein precursers which 
release T-kinin in the presence of trypsin are T-kininogen I and II 
(Okamoto and Greenbaum 1983a; Okamoto and Greebaum ,1986.) Free .... 
T -kinin is released during an inflammatory response into the blood and 
inflammatory fluid (Barlas et al., 1986). 
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1.2.3 Other Mammalian kinins. 
Werle and Preisser(195~ noticed that some bacterial proteases 
release a substance from milk which stimulates smooth muscle 
. preparations, a peptide named colostrokinin. Later Guth found that calf 
saliva or sheep urinary kallikrein liberates colostrokinin from a':id-heated 
bovine colostrum (Guth, 1959; Moriya et al.,1966). Submaxillary, 
urinary and pancreatic kallikrein, trypsin and chymotrypsin, liberate 
colostrokinin (Werle and Trautschold, 1960) although serum 
kallikrein is found to be inactive in these studies. The actions of this 
peptide are qualitatively similar to bradykinin, but relatively stronger 
in increasing capillary permeability. Its effects are partially destroyed 
by trypsin. The molecular weight of this kinin is 2000 and the N- and 
C- terminal aminoacids are different from those of bradykinin 
(Yamazaki and Moriya 1969). 
1.2.4 Non-mammalian kinins. 
Observations of the first nonmammalian kinin, wasp kinin, have 
been \made by Schachter and Jaques. Substances of possible polypeptide 
nature were detected in venom of wasp (Polistes kinin), hornet and 
scorpion (Jaques and Schachter, 1954; Holdstock et al., 1957; Diniz and 
Moura Gonclaves,1960; Bhoola and Schachter, 1962). From the extract of 
venom of the wasp Megascolia flavifrons two kinins, Thr-6 bradykinin 
and Thr-6-bradykinin-Lys-Ala, have been identified. The bradykinin 
like effects on a number of vertebrate smooth muscle preparations have 
been explained by the action of these kinins (Yasuhara et al., 1987). The 
venom of Phoneutria nigriventor spider induces increase in vascular 
permeability_ in rabbit skin by activation of the tissue kallikrein kinin 
system of rabbit. The oedema ing~ced by this venom is potentiated by the 
kininase II inhibitor, captopril and inhibited by B2 receptor antagonists 
.:or 
like Hoe 140 (Marangoni et al., 1993). Ornithokininogen has been isolated . 
from chicken plasma. Its molecular weight is estimated as 7 4,000 and is 
found to have properties similar to those of mammalian high molecular 
weight kininogen in terms of aminoacid composition and susceptibility to 
plasma ,kallikreins. The structure is determined as Arg-Pro-Pro-Gly-
Phe-Thr-Pro .. Leu:.:Arg; It is similar to bradykinin except for substitution 
of Thr-6 and Leu-8 for Ser-6 and Phe8. It induces contraction of 
7 ' 
; chicken smooth muscle and has strong hypotensive effect on the chicken 
(Kimura et al., 1988). Like birds, the snake Bothrops jararaca has been 
suggested to have its own kallikrein-kinin system.The venom causes a 
fall in the carotid artery pressure of the anaesthetised snake. This effect 
is tachyphylactic and is potentiated by captopril, a kininase II inhibitor. 
Incubation of Bothrops jararaca plasma releases a subst.ance that 
produces hypotension and contraction of Bothrops jararaca uterus. Like 
mammalian kinins this substance is dialysable, thermostable in acid pH 
and is inactivated by chymotrypsin (Abdalla et al., 1989). 
Cellular actions of kinins 
. The cellular actions of kinins are modulated by specific receptors. 
The kinin receptor stimulation causes activation of several second-
messenger systems, such as arachidonic acid products, calcium, cyclic 
AMP, and cyclic GMP (Freay et al., 1989; Burch and .Pasquale, 1990). 
Kinins also stimulate the secretion of renin from kidney (Beierwaltes 
and Carretero, 1986), release of vasopressin from the neurohypophysis 
(Baertschi et al., 1981) and secretion of catecholamines from the adrenal 
meddHa (Staszewska-Barezak and Vane, 1967). The effects of kinins in 
biological fluids are very short lived because they are rapidly destroyed 
by kininases. The half-life of bradykinin and lys-braykinin in blood is 
estimated to be less than thirty seconds (McCarthey et al., 1965; 
Ferreira and Vane, 1967). 
Kinin Receptors 
The various physiological effects of kinins are mediated by specific 
receptors which are widespread and belong to two major categories B 1 
and B2 (Regoli and Barabe,1980). By activating B1 and B2 receptors 
and possibly by other mechanisms (Rhaleb et al.,1988) kinins exert a 
variety of biological effects. The two receptor hypothesis has been 
confirmed by data obtained with antagonists. Antagonists for B 1 
receptors were identified as des-Arg9-bradykinin and des-Arg 10-
kallidin. B2 antagonists were identified by replacing Pro7 with D-Phe in 
bradykinin (Vavrek and Stewart, 1985). Most of the well chanicterised 
actions. of- bradykinin and kallidin appear to be mediated by activation of 
the B2 receptors. These effects include cell retraction, vascular smooth 
8 
. ~ ... 
muscle relaxation, contraction of visceral and bronchial smooth muscle 
and activation of peripheral afferent C type nerve fibres (Steranka et al., 
;:1989). In contrast to B2 receptors, B 1 receptors seem to be absent 
i~onnally, and become evident in some pathological states, particularly 
tjit inflammmation and . after exposure of the tissue to noxious stimuli 
[(Regoli et al., 1981). The primary endogenous agonist for the B1 
!"'I' 
'r.receptor is des-arg9-bradykinin, the metabolite that results from the 
hydrolysis of the C-terminal arginine of the kinin moity. Whereas the B2 
receptor has been cloned, the inflammation induced B 1 receptor has been 
eluding molecular· biologists. 
Recent findings suggesting the existence of new receptor types 
namely, B3, B4 and Bs have been analysed critically, especially with 
reference to the criteria used for affirming their existence. The 
pharmacological characteristics of the receptor B2 show differences 
between species, and two subtypes- -B2A (rabbit, dog and possibly man) 
and B2B (guinea pig, hamster, rat) have been proposed. A third 
receptor, B3, has been proposed to explain the unusual oehaviour of the 
trachea of guinea pigs to kinins. But its significance in humans is not 
known (Regoli et al., 1993). 
\ 
T-kinin 
The vascular responses of T -kinin are similar to bradykinin. It 
signifidmtly increases the vascular permeability in a dose-dependant 
manner. Prostaglandin E 1, forskolin and the angiotensin converting 
enzyme inhibitor SQ 14225, potentiate the T-kinin induced plasma 
exudation. Hence T-kinin i~ suggested to have a major role in increasing 
vascular permeability associated with inflammation (Sugio and 
Greenbaum, 1988). The diminution of inflammatory response observed 
following thyroidectomy is suggested to be mediated at least in part by 
T -kinin. Thyroid hormones increase and hypothyroidism decreases the 
inflammatory responses. It has been demonstrated that T -kinin is greatly '"' 
increased and bradykinin slightly increased after thyroidectomy and that 
T-kinin concentration in T-3 treated thyroidectomized animals is almost 
restored to control level. The ability of thyroidectomized animals to 
produce , higher plasma T-kininogen compared to euthyroid animals 
when stimulated by · laporotomy has been documented. There is a four 
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fold increase in T-kininogen production in the former (Bouhnik et 
a1.,1988). 
The gene for T-kininogen is not present in human. Howe\'er, 
, Wunderer et al., (1986) have isolated T-kinin from the ascites fluid of 
patients with ovarian carcinoma indicating the presence of a protein 
carrying the T-kinin molecule in the cancer cells.T-kinin has been 
:identified in various human malignant exudates (Wunderer et-af., 1990). 
Yet, it is not known whether the leukokininogen and leukokinin-H 
released by cathepsin Dare the components of the T-kinin system, which 
has been reported by Wunderer (Grebow et al.,)979; Roffman and 
Greenbaum, 1979). T -kinin probably acts through kinin B2 receptors in 
the rat uterus. While the potency of T -kinin is similar to bradykinin the 
affinity of T-kinin to the receptor is ten-fold lower than that of 
bradykinin. However, the D-isomer ofT-kinin has an affinity greater 
than that ofT-kinin and is more potent in causing contraction. The data 
from binding studies on T-kinin analogues suggests tha! the substitution 
of hydroxyproline for Pro-5 together with the D-configuration at Ile-1 
and/or Ser-2 may be useful in the development ofT-kinin antagonists 
(Gao et al., 1993) 
R~cent studies indicate that in the rat kidney, T-kinin is converted 
into bradykinin, probably by aminopeptidase M. Kininase I inhibitor, 
Mergetpa does not affect the conversion while the kininase II inhibitor, 
BPP 9a increases the proportion of T-kinin converted to bnidykinin 
(Viera et al.,1994). 
1.-3. Kinin-forming enzymes. 
The kinin forming enzymes- -are also known as kininogenases or 
kallikreins. They have been regarded as a group of trypsin-like serine 
proteases t~at liberate an extremely biologically active peptide, kinin, 
from plasma kininogens (Webster, 1970). The kininogenases include 
plasma and tissue kallikreins and T-kininogenases. 
Kallikreins 
The kallikreins have been separated into two classes - those ·derived 
from glandular-sources, named tissue kallikrein and those derived from 
plasma named plasma kallikrein which differ in their molecular 
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A . weigh~, origin, biochemical properties and biological actions on ]flasma 
r . kininogens. All known plasma kallikreins are inhibited by soybean ;,~) trypsin inhibitor (SBTI) (Werle and Maier, 1952; Bhoola 'et a!., 
,~i 1960),whereas the tissue kallikreins are not (Back and Steiger, 1968). 
i~. ·· In addition, the plasma kallikrein, in most species except the guinea 
{ pig, releases kinin only from high molecular weight kinin!>gen (Y ano 
et al., 1967), while tissue kallikrein releases kinin from low and high 
molecular weight kininogen. 
1.3.1 Plasma kallikrein. 
The kallikreins of all mammalian plasma is seen in the form of an 
inactive precursor, prekallikrein. It is also known as Fletcher factor, 
because the deficiency of prekallikrein was first noticed . in a patient 
named Mr. Fletcher (Wuepper, 1973a). Prekallikrein is a single chain 
glycoprotein synthesised in the liver. It is a member Qf single gene code 
(Seidel et al., 1989). It is present in plasma as a complex bound to high 
molecular weight kininogen (Mandle et al., 1976; Mandle and Kaplan, 
1977). Plasma prekallikrein can be activated by Hageman factor and 
high molecular weight kininogen is converted to active bradykinin 
(Mandie et al., 1976; Kaplan et al., 1992). Inactive Hageman factor is 
activated by kallikrein through a positive feedback mechanism (Cochrane 
et al., 1973). Activated Hageman factor and piasma thromboplastin 
antecedent (factor XI) circulate bound to high molecular weight 
kininogen. Inactive factor XI is, therefore, converted to active factor 
XI A . through high molecular weight kininogen to participate in the 
intrinsic coagulation pathway (Ratnoff et al, 1961). Prekallikrein can also 
be activated by acetone (Kraut et al., 1928); caseine (Werle, 1936), 
trypsin (Werle et al., 1955) and negatively charged surfaces such as 
glass, kaolin, fused alumina and celite (Margolius, 1963). 
.:¥ 
In addition to its role as an intermediate in bradykinin generation 
(Wuepper,1972, 1973b; Weiss et al., ·1974; Seito et al., 1974) kallikrein 
is found to be required for normal functioning of· coagulation pathway 
and plasma fibrinolytic pathway, and chemotaxis (Kaplan and Austen 
1972a; Kaplan et al., 1973). Prekallikrein has been identified as the 
factor (Wuepper;-1972, 1973a) genetically deficient in members of the 
-~Fletcher family (Hathaway et al., 1965). It may also function as the co-
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factor in the fibrinolytic pathway (Wuepper, 1973b) along with Hageman 
factor (Iatridis and Ferguson, 1961, 1965; Niewiarowski et al., 1959), the 
plasminogen proactivator (Kaplan and Austen, 1972b) and plasminogen. 
1.3.2 Plasma kallikrein inhibitors 
. 
A system in the body having as potent a biological activity on the 
kininogenase.,.kinin system requires a regulating mechanism that limits 
the concentration of the active p-rinciples. The inhibition of the 
proteolytic enzymes by extract of plants (plant .inhibitors) or animal 
tissues (natural inhibitors) was first recognized by Frey et al., (1930) 
when he injected blood contaminated urine into anaesthetised dog and 
found that it was completely inactive on the blood pressure. The general 
characteristics of the reactions of the proteinase inhibitors with the 
enzymes are: (1) pH-dependant forming of an enzymatically inactive 
. complex with the enzyme at a definite molar ratio, (2) rapid equilibrium 
of the reaction, and (3) finally complete recovery of activity of the 
enzyme after splitting the complex. 
Plasma kallikrein is rapidly inactivated by Chloride inhibitor· which 
inactivates both plasma kallikrein and Hageman factor. Further a2 
macroglobin, antithrombin III and a 1 antitrypsin have been identified 
as plasma kallikrein inhibitors (Fritz et al., 1979). The salivary gland 
secretion of medicinal leech is found to contain plasma kallikrein 
inhibitor activity which is capable of blocking the amidolytic activity of 
the enzyme in an irreversible manner (Baskova et al., 1988). 
1.3.3 Tissue kallikreins 
Kallikreins derived from glandular sources are generally termed 
tissue kallikreins. Tissue kallikreins are kinin serine proteases which 
release kallidin from kininogen substrate (Pierce and Webster, 
1961).The occurrance and distribution of tissue kallikrein genes have 
been evaluated (Drinkwater et al., 1988). Human pancreatic and ren,al 
kallikreins possess identical aminoacid sequences and no more than three 
closely related genes (Baker and Shine, 1985; Schedlich et al., 1987), 
while in, the mouse the kallikrein group of serine proteases consist of 
twenty~Jour-·highly homologous genes (Evans et al., 1987). In human, 
tissue kallikrein gene family comprises the hRkall, hGK-1 and PAS. 
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These .are clustered on the long arm of chromosome 19q13-3-13-4 
(Evans et al., 1988; Morris, 1989; Clements, 1994). In mouse. and rat 
kallikrein activity is associated with the highly conserved members 
of a large multigene family located on chromosome seven (Richards et 
al., 1982; Mason et al.? 1983; Schedlich et al., 1988). 
Structure and Specificity 
Tissue kallikreins isolated from different exocrine and endocrine 
glands indicate their initial ·synthesis as 37 ,OQO or 30,000 dalton 
prepropeptides which are converted into a 38,000 dalton active form 
by proteolytic processing and glycolysation. The active kallikrein is 
capable of binding to an inhibitor to form a 92,000 dalton inhibitor 
complex. (Chao et al, 1986). Although,they are physico-chemically, 
enzymatically and immunologically identical, tissue kallikreins perform 
different functions at different anatomical sites depending on the 
electrolyte and endocrine control (vanLeeuwen et a(,1984). 
Sources 
-- \ 
Tissue kallikreins have pyen detected in pancreas (Frey et al., 
1968),gastro-intestinal mucosa (Zeitlin and Smith, 1973; Seki et 
al.,l972), salivary glands (Bhoola and Ogle, 1966) and renal cortex 
(Nustad,~ 1970).They have also' :.been identified in uterus (Marlis et al., 
1982), and rabbit foetal placenta (Weerasinghe and Gadsby, 1992). 
Pancreatic kallikrein. 
All mammalian species so far investigated contain pancreatic tissue 
kallikrein. In the pancreas, tissue kallikrein is found at the level of rough 
endoplasmic reticu~um and mainly in the zymogen granules of 
pancreatic acinar cells. They are not found in the cento-acinar cells of 
duct cells (Amouric et al., 1982). Human pancreatic kallikrein is stable 
at pH 8 and is rapidly inactivated at pH 2.6. It i5> a glycoprotein with a 
molecular weight of 35,000. The enzyme is inhibited by aprotinin but 
not by ovomucoid, soybean trypsin inhibitor or limabean· inhibitor 
(Amouric·-and Figarella, 1980). 
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Urinary kallikrein. 
• 
It has been reported that urinary kallikrein is derived mainly from 
renal cortex (Nustad,l970). Man excretes about 200-210kallikrein units 
per day (Frey et al.,1968). Although, urinary kallikrein .has been 
reported to be derived mainly from renal cortex, its secretion into the 
urine is not the exclusive mechanism of excretion of tissue kallikrein 
into urine. A second mechanism, the renal transfer of endogenous tissue 
kallikrein from blood into urine can contribute to the urinary kallikrein 
(Fink and Schleuning, 1982). 
Cardiac tissue kallikrein 
Tissue kallikrein has been detected in rat cardiac tissue. In · addition, 
the mRNA which codes for glandular kallikrein has.been found in the 
ventricles (Nolly et al., 1992). 
Functions 
\ 
In addition to their classical role as bradykinin-releasing enzymes 
tissue kallikreins are known to ,be involved in the post translational 
modification of protein llorrltohe~.~t\4j~rowth factors (Weerasinghe and 
Gadsby, 1992). Re·cently, th¢ 'possibility of tissue kallikreins being 
powerful modulators of blodd.~ressurb has been proposed. Transgenic 
mice overexpressing human tissue kallikrein had been developed. The 
mice had significantly lowered blood pressure. Administration of 
aprotinin, a potent tissue kallikrein inhibitor restored the blood pressure 
back to normal (Wang et al., 1994). 
1.3.4 Tissue kallikrein inhibitors 
Tissue kallikreins have been regulated by a number of plasma serine 
protease inhibitors. All substrate analogues ·occurring within the 
sequence Ser386-Pro-Phe-Arg-Ser-Val-Gln392 from bovine kininogen 
are tested for inhibitory activity. The heptapeptide Ac-Ser-Pro-Phe-
Arg-:Ser!' Val-Gln-NH2 is the most effective inhibitor. The N- terminal 
seryl residue (P4) and the prolyl residue (P3) slightly improve the 
14 
\ inhibitor action. The phenylalanine residue at P2 appears to have a 
_: more pronounced effect. The arginyl residue at P1 and seryl residue at 
P2 appear to be the most important ones in the inhibitory sequence: The 
valyl residue at P2 and C-terminal glutaminyl residue improve the 
inhibition. Almost eighty percent of !he binding energy of the inhibitors 
comes from the core sequence Plie-Arg-Ser which occurred between P2 
and Pl (Deshpande and Burton, 1992).Inhibitors of kallikrein were first 
described i!l many bovine organs such as lung, pancreas and kidney 
(Kraut et al, 1930). They inhibit tissue kallikrein and a number of other 
proteases including trypsin (Vogel and Werle, 197.3). Another kallikrein 
binding protein has been identified in the serum, lung and liver of rats. 
This inhibitor specifically binds to active tissue kallikrein and not to 
inactive tissue kallikrein and plasma kallikrien. Protein C inhibitor, a 
relatively nonspecific heparin-dependant serine protease inhibitor 
present in plasma and urine inhibits the amidolytic activity of tissue 
kallikrein by formation of PCI- tissue kallikreiq complex. This 
inhibitor may be identical with kallikrein binding protein (Ecke et 
al.,1992). Kallistatin another member of the serpin (serine proteinase 
inhibitor) family inhibits human tissue kallikrein by formation of an 
equilholar complex and by generation of a small carboxyl terminal 
fragment from the inhibitor due to cleavage at the reactive site by tissue 
kallik-rein (Zhou et al., 1992). 
1.3.5 T -kininogenases 
T -kinin is released by acid proteinases of granulomatous tissue in 
rats with Carrageenin induced inflammation. Two types of acid 
proteinases seem to be responsible for kinin release. One is identified as 
Cathepsin-D. Cathepsin-D does not release T-kinin alone but T-kinin 
containing peptides, T-kinin Leu (Sakamoto et al., 1988) and Met-T-kinin 
as well (Sakamoto et al.,l987). T-kininogenases like enzyme has been 
found in rat and mouse submandibular glands and in rat peritoneal 
white cells. This enzyme belongs to a group of structurally similar yet 
distinct kallikrein like ~erin~~~p~oteases., The purifi-ed protein has an 
apparant molecular weigh,~ ~:~,f.t,t~i~~Yr~~~~p~ thousand. It is kinin.ogenase 
and not esterase activity that c:~n:iQ¢1 e1.1.l\anced ten-fold in -the presence of 
• • • :. . ,'' .. ·~.,:;,;~.:!~~~'·~··:::!:!:': (:'·.·.:!~i·!:· ' 
dtthwthrettol-{Barlas., 1987).:':,:~!Wlf~·~;''- \ ;-'.~,:· 
' , I 
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1.3.6 T-kinin inhibit()r~ ·· .. 
The esterolytic is inhibited by soybean 
trypsin inhibitor and .lima bean and ovomucoid 
trypsin inhibitors enzyme is locali~ed at the 
granular convoluted in rat submandibular 
glands (Xiong et al., 1 te specificity, pH optimum 
and agents which activity indicate that this 
enzyme is different from · · · 'kallikreins, cathepsin D and 
other known kininogenases. Thus, the rat seems to have· a complete T-
kininogenase-T-kinin system (Barlas et al., 1989). 
1.4 Plasma Kininogens. 
1.4.1 a & b High Molecular Weight kinino.gen and Low 
M-olecular yveight kininogens 
Kininogens are extremely versatile proteins which serve a plethora of 
distihct biological roles and their functional diversity is reflected by a 
complex multidomain structure. They have multifunctional domains; an 
aminoterminal domain for cysteine proteinase inhibitor, a bradykinin 
moity and in the case of high molecular weight kininogen a carboxyl 
terminal domain for a cofactor of blood coagulation (Kitamura., 
1987). Plasma kininogens include low molecular-weight kininogen, high 
. . 
molecular-weight kininogen (Jacobsen,1966a, 1966b; 1966d,) and T-
kininogen (Okamoto and Greenbaum, 1983a). 
Structure and Specificity 
Two kinds of kininogens with different susceptibilities to plasma 
kallikrein have been found in the plasma of human beings, dogs, rabbit, 
rat and guinea pig. Kininogen I a glycoprotein with molecular weight 
76000 containing 12.6% carbohydrate and 581 aminoacid residues is 
called high molecular weight kininogen. Kininogen II also a 
glycoprotein with molecular weight 48000 containing ' 19.8% 
carbohydrate· and 356 aminoacid residues is termed low molecular 
weight kininogen (Yang et al.,1971). Pierce, (1970), purified and 
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distinguished them from each other by DEAF-Sephadex A-50 
chromatography and polyacrylamide gel electrophoresis. Plasma 
kallikrein releases kinin from high molecular weight kininogen by 
sephadex G-200 gel filtration. Human low molecular weight kininogen is 
. a single chain glycoprotein of molecular weight 68,000 which is 
ctmverted to a two- chain protein by limited proteolysis ~ith tissue 
kallikrein to form a heavy chain (molecular weight 62,000) and a light 
chain (molecular weight 4000). Human high molecular weight kininogen 
represents a single chain glycoprotein of molecular weight 114,000, 
which is split into two chains of similar size (H -chain molecular weight 
58,000 and L-chain, molecular weight 62,000) by limited proteolysis 
with tissue kallikrein. Purified kininogens readily form self-aggregates 
ranging from dimer to hexamer (HMW kininogen) and from dimer to 
decamer (LMW kininogen) respectively (Mori and Nagasawa., 1981). 
Sources of kininogens. 
The primary, though not the exclusive source of kininogen are the 
parenchymal cells of the liver(Chao et al., 1988). Immunohistochemical 
studies have detected kininogens in the acinar cells of rat 
submandibular glands (Chao et al., 1988), and in distal tubular and 
upper collecting duct cells of human kidney (Proud et al., 1981). 
Presence of kininogen in human platelets has been reported (Schmaier et 
al., 1986). Yet, it is not known whether kininogen originates from these 
cells or is taken up from plasma derived body fluids. Immunoreactive 
. 
kininogen has been localised in the principal cells of collecting ducts and 
tissue kallikrein has been detected in the connecting tubule cells, segment 
of the nephron preceding the cortical collecting ducts. This anatomical 
relationship is in accordance with studies that described intermingling 
of principal_ cells and connecting tubule cells where connecting tubules 
merge into cortical collecting_ ducts in the human nephron. The .... 
relationship between cells that contain tissue kallikrein and its substrate, 
kininogen, suggest that kinins can be generated in the lumen of distal 
cortical segments of human nephron. 
At least four types of kininogen mRNAs exist in rat liver. Two of 
them are low molecular weight kininogen mRNA and high molecular 
weightkininogen · mRNA, while the other two are T -kinin encoded 
mRNA. The two T-kininogen mRNAs dramatically increase after 
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induction of acute inflammation and T -kininogen turns out to be identical 
with· alpha 1 major acute phas~ _protein. 
• 
Functions of kininogens. 
Kininogens function as the large precursor molecules to small 
vasoactive peptides, the kinins. Kinins are released from the single 
chain kininogens of molecular weight 68000 (low molecular-weight 
kininogen) and 110,000 (high molecular weight kininogen) via limited 
proteolysis with specific kininogenases like kaJlikreins. High molecular 
weight kininogen and prekallikrein are among the large number of 
proteins that are involved in the cascades that initiate and propagate 
blood coagulation. In concert with Hageman factor and factor XI they 
trigger the . intrinsic blood coagulation via the contact activation 
pathway (vanlwaarden and Bouma,1987). Kininogens are potent 
inhibitors of cysteine proteinases (Sueyoshi et ~1.,1985). Structural 
analysis indicates that the inhibitor domains of kininogen are similar to 
the low molecular weight cysteine proteinase inhibitors of the stefin 
and cystanin type. In addition, it has been proposed that the kininogens 
ahse from cystatins by gene triplication (Muller- Esterl et al., 1985). 
1.4.1c T-kininogen 
T-kininogen is a unique protein forming the substrate for T-kinin,a 
potent pharmacological mediator of inflammatory response (Okamoto 
and Greenbaum, 1983a). Unlike high molecular weight kininogen and low 
molecular weight kininogen, T -kininogen is an acute phase protein that 
makes up ninety percent of plasma kininogen content following an 
injection of Carrageenin. This work is confirmed by demonstrating that 
the mRNA of T -kininogen in rat liver increases following an 
inflammatory challenge while mRNA of other kininogens does not 
(Kagayama et al.,1985).It is a thiol protease inhibitor and can inhibit a 
variety of enzymes including Cathepsin B (Okamoto and Greenbaum, 
1983b ). It is not a substrate for plasma and tissue kallikreins but it serves 
as a substrate for thiol activated kininogenases present in rat and mouse 
submandibular glands (Oh-lshi et al., 1982). It is synthesised in the liver 
in enormous-quantities following an inflammatory response (Barlas et 
al., 1987). It is found to be present in normal concentrations in Brown-
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'(Norway Katholeik strain of rats (Sueyoshi et al.; 1985). Its plasma level 
::!,is reduced following administration of anti-inflammatory drugs 
t (Barlas et al., 1986).The female rats have a higher plasma level of T-
•r 
·: kininogen than males.Lactating females and new born have very high 
;F circulating .levels. 
t:-
~'· ~~ 1.5. Fate of kinins 
1.5.1 Kininases 
Kininases are peptidases that inactivate kir~ins. Bradykinin is 
susceptible to degradation by a variety of endo and exopeptidases. The 
main enzymes which metabolize bradykinin are kininase II or 
angiotensin converting enzyme and kininase I or carboxy-peptidase N 
(Erdos, 1990). Kininase I family comprises of kininase I-CPN and 
kininase I-CPM. Other kininases -include aminopeptidase P, maprin, 
endopeptidase 24.15, prolyl endopeptidase, neutral endopeptidase, 
. 
carboxypeptidase M and diamidase. These peptidases are widely 
distributed in various tissues and cells in the body and their subcellular 
locations vary as well. As bradykinin is inactivated when any of its 
peptide bonds are cleaved all these enzymes qualify as potential 
kininases in vivo (Seidgel, 1992).The relative importance of each of 
these peptidases in controlling the kinin levels varies with species, type 
of biological fluid and tissue site of formation of the peptide.ln human 
the circulating bradykinin is primarily regulated by kininase I-CPN but 
on endothelial surface, particularly in the pulmonary vascular bed, by 
kininase II. In contrast the most potent kinin-degrading enzyme in rat 
plasma is kininase II (Ishida et al,1989). 
Circulating carboxypeptidase-N and membrane bound 
carboxypeptidase -M cleave the C- terminal arginine to produce des-arg9-
bradykinin. Angiotensin converting enzyme or kininase II cleaves two 
inner peptide bonds producing completely inactive metabolites. 
Aminopeptidases remove the amino terminal arginine and in addition a a 
neutral endopeptidase, that occurs both in circulation and tissues, 
probably degrades the molecule into . even smaller. peptide fragments. 
Two additional endopeptidases designated as kininase A and B have be~n 
identified in the synaptic membranes of rabbit brain (Camargo et al., 
1973). ·-· - .. --- ' -- --
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,::1.6 Role of kinins . 
.) .. 6.1 Physiological actions of kinin. 
.'f' 
./~ 
:A:: 
• 
i'.Y Kinins are present as large precursor molecules originating in the 
?:liver and contained in high concentrations in the circulating blood. They 
!;are released only when plasma or tissue kallikreins are activated by 
various stimuli. Kinins are released locally to act as autocoids and to be 
rapidly inactivated either at the site of release or in circulating blood or 
the kininases of lung. Some of its physiological func~ions are: 
Vasodilation. 
In animals and man, bradykinin is one of the most potent 
vasodilator substances known. The hypotensive effect of kinins are 
attributed to the peripheral vasodilation and may be the result of a 
. complex mechanism. Kinin receptors are found in the endothelium, 
smooth muscle membrane, autonomic nerve terminals and in other 
cells such as mast cells, blood cells and fibroblasts. When activated, these 
receptors may act directly to modify the cell membrane function or 
indirectly by promoting the release of other endogenous agents which 
change the membrane functions and produce vasodilation. B2 receptors 
have been demonstrated to be present in endothelia where they promote 
the re.lease of endogenous vasodilators, endothelium derived relaxing 
factor and prostacycline which act by reducing the tonus of the 
neighbouring- smooth muscle ((D'Orleans et al., 1985: Cahille et al., 
1988). However in some vessels,-- for instance, the renal artery of dogs 
B 1 and B2 receptors appear to be present in the smooth muscle fibre, 
acting directly by promoting the formation of prostaglandins, which 
inhibit smooth muscle tone (Rhaleb et al,1988). 
Vascular permeability. 
In peripheral vessels, kinins act at the capillary. and venous level 
by increasing vascular permeability. The site of action appears to be 
the endothelial cells which contract in response to kinins and in this way 
increase.the vascular permeability (Haddy et al., 1970). 
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.~fVenoconstriction. 
til: • 
l 
~~· Kinins act at the venous level by stimulating the venous smooth 
§ muscle. Isolated large veins from several animal species have been 
¥ shown to be sensitive to kinins and to contract in response to 
f bradykinin (Regoli and Barabe, 1980). Receptors for kinins, both B1 and 
B 2 types appear to be present in smooth muscle rather than in 
endothelia, since venous endothelium does not play any major role 
(DeMay and Vanhoutte, 1982: Seidell and La Rochalla, 1987).These 
effects are extremely important since kinins are among the endogenous 
agents involved in the response of tissues to inflammatory stimuli and in 
allergic reactions (Regoli, 1985; Baumgarten et al., 1985). 
Release of endogenous agents. 
A variety of endogenous agents are activated by kinins. Synthesis and 
release of prostaglandins are stimulated by kinins (Nasjletti, and Malik, 
1979). Kinins release prostaglandins by activating B1 and B2 receptors 
(Rhaleb et al., 1988). With regard to histamine release, kinins particularly 
kallidin and B2 receptor antagonists , have been found to be potent 
histamine releasers in the rat (Johnson and Erdos, 1973; Devillier et al., 
1985). This appears to be a nonspecific phenomenon common to peptides 
containing ·positively charged aminoacids and is probably not due to 
activation of receptors. 
Bradykinin and Smooth muscle 
At extremely low concentrations bradykinin produces contraction and 
relaxation of smooth muscle in the gastro-intestinal and urogenital tract. 
At the target organ, bradykinin interacts with discriminator proteins of 
the plasma membranes and triggers, via changes in certain membrane ,,. .. 
functions, its biological responses. The binding to the discriminator 
makes specific demands on the nonapeptide. The binding results from 
an angular confirmation which existed in the solution. The complete 
sequence is responsible for the specific confirmation. Consequently, the 
biological-activity ·of --partial sequences is low. The bradykinin induced 
changes in enzyme activity are connected with other effectors like 
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l prostagl~ndins and calcium ions. The calcium ion dependance of the 
f1 effect of bradykinin on guinea pig ileum and rat uterus indicates the 
•;it . . ·~ importance of these ions as additional -second messengers. BradyKinin 
r. stimulatesthe influx of calcium ions into the ileum. It has been found to 
J be ineffec:tive if no extracellular calcium is available (Paegelow et al., 
; 1979; Innis et al.,1981). 
1.6.2 Pathological conditions 
Diabetes Mellitus 
Diabetes mellitus is associated with abnormal renal haemodynamics 
and renal electrolyte metabolism. Renal kallikrein and its kinin products 
have a role in renal haemodynamic regulation (Levy et al, 1977). 
Kallikrein containing cells of the rat and human are adjacent to the 
. glomerular afferent arteriole. Intact glomeruli have specific sites for 
kinins. Kinins can stimulate eicosanoid production by both ~fferent 
arterioles and glomerular mesangial cells. Hence ,kallikrein-kinin 
system may participate in the tubulo-glomerular feedback mechanisms 
that tegulate glomerular function. Kinins can ·also cause changes in 
electrolyte and water transport in renal tubules and other transporting 
epithelia. Developj.lent of systolic hypertension and reduced urinary 
kallikrein have been reported in diabetes. Early alterations of renal 
kallikrein kinin system in diabetic states are suggested to contribute to 
the development of hypertension in diabetes (Pellufo et al., 1992). 
Hypertension and cardiac hypertrophy 
Kinins are potent vasorelaxant peptides which cause an important 
contribution to blood pressure homeostasis (Sharma, 1989; 1988a).The 
functions of kinins in relation to blood pressure regulation are 
vasodilation, reduction of peripheral resistance and regulation of sodium 
excretion (Adetuyibi and Mills, 1972). An intrarenal hormone system has 
been suggested to control water and electrolyte excretion and thus 
participate in blood pressure regulation (Carretero and Scicli, 1981). 
Alterations in tissue structure appear in the myocardium in hyehensive 
states including ·a ·remodelling of intramyocardial coronary arterioles 
and a disproportionate accumulation of fibrillar collagen within their 
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\t adventi~ia· and neighbouring interstitial space. These expressions of 
;,, fibrosis appearing in hypertensive hypertrophic heart are linked with 
~- ' . 
. ··· · renin-angiotensin system. Bradykinin receptors have been identified in the 
myocardium. A nonendothelial tissue angiotensin converting enzyme 
whose binding density is marked in the matrix of heart valves, adventitia 
and sites of fibrosis has been identified. This enzyme may be rvsponsible 
for regulating concentration of angiotensin II and bradykinin that 
govern fibroblast collagen turnover. The cardioprotective effect of 
bradykinin by inhibition of noradrenaline liberattion mediated by B 1 
receptor activation has also been suggested (Chahine et al., 1993). 
lnflamma tion 
Kinins are peptide mediators which are produced early in and 
throughout an inflammatory episode. They are capable of producing all 
of the observed cellular effects such a~ vasodilation, . venoconstriction 
and endothelial cell retraction that result in vascular leak and pain. 
Kinins also have the capacity to release transmiitters from nerve 
terminals (substance P), stimulate synthesis of cytokines, induce 
formh.tion of prostaglandins and release endothelium derived releasing 
factor from endothelial cells. Hence many of the inflammatory and 
vascular dis<?rders involve kinins in their pathogenesis. 
1. 7 Antihypertensive agents 
Angiotensin converting enzyme inhibitor 
Angiotensin converting enzyme inhibitors are established in the 
treatment of hypertension.The hypotensive effects of these inhibitors 
like captopril are due to reduction of the peripheral resistance and 
increased blood flow to the organs. Captopril acts by inhibition of ACE __ 
... 
enzyme itself. Some of the antihypertensive effects occur through non 
angiotensin II mediated mechanisms like decreased kinin degradation 
leading to enhanced production of vasodilators, arachidonic acid 
metabolites (Smith et al., 1993). Earlier reports indicating an increase of 
plasma kinin and decrease in plasma angiotensin are available (Iimura, 
Shimamoto, l989).Renal kallikrein kinin system has a contributing role in 
the hypotensive effect of captopril (Dessi-Fulgheri et al., 1993). 
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.~; There have been conflicting reports about effects of angiotensin 
f convertihg enzyme inhibitors on insulin sensitivity and glycemic 
':~ ~ontrol. Studies with captopril have been shown to increase in.sulin 
k' sensitivity and that this is due to enhanced glucose uptake into skeletal 
1{~ muscle. Hence, a modest effect of angiotensin converting enzyme 
Y inhibitors that they enhance insulin mediated glucose uptake. The 
mechanism of this effect is likely to be a combination of increased 
muscle blood flow, local renin-angiotensin system blockade and 
elevated kinin levels (Donnelley, 1992). Recent reports indicate that the 
improvement in insulin sensitivity produced by ACE inhibitor is kinin 
dependant and not on angiotensin II antagonism (Tomiyama et al, 1994). 
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